Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
Conditions
Interventions
Otilimab
Placebo 1
+2 more
Locations
120
United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Winfield, Illinois, United States
Start Date
May 28, 2020
Primary Completion Date
July 15, 2021
Completion Date
August 16, 2021
Last Updated
September 23, 2024
NCT05543616
NCT06409663
NCT04402957
NCT05677893
NCT04466241
NCT05693272
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions